Medpace Holdings (MEDP) Prices 7M Common Stock IPO at $23/Share, at High-End of Expectations
- AT&T (T) to Acquire Time Warner (TWX) for $107.50/Share
- Rockwell Collins (COL) to Acquire B/E Aerospace (BEAV) for $6.4B
- China Oceanwide to Acquire Genworth Financial (GNW) for $2.7B
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Medpace Holdings, Inc. (Nasdaq: MEDP) announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share. All of the shares of common stock are being offered by Medpace. In addition, Medpace has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock from Medpace at the initial public offering price, less underwriting discounts and commissions. Medpace’s common stock is expected to begin trading on the NASDAQ Global Select Market on August 11, 2016 under the ticker symbol “MEDP,” and the offering is expected to close on August 16, 2016, subject to customary closing conditions.
NOTE: The company was previously expecting a range of $20 - $23 per share.
Medpace intends to use the net proceeds of this offering to repay a portion of its outstanding borrowings under its senior secured term loan facility.
Jefferies LLC and Credit Suisse Securities (USA) LLC are acting as joint lead book-running managers for the offering. UBS Securities LLC and Wells Fargo Securities, LLC are also acting as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated and William Blair & Company, L.L.C. are acting as co-managers for the offering.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,300 people across 35 countries.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- iRhythm Technologies (IRTC) Prices Larger Common Stock IPO at $17/Share, Above Expected Range
- OutMatch Dives Into HR Analytics at Inaugural Customer Conference
- Forterra (FRTA) IPO Opens Down 8%
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, IPOs
Related EntitiesCredit Suisse, UBS, William Blair, Jefferies & Co, Robert W Baird, Wells Fargo, IPO
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!